Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas
  
ADC
Astellas licenses Evopoint's CLDN18.2-targeted ADC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Therapy Areas